This report was first published by Endpoints News. To see the original version, click here
Sanofi has paid $135 million upfront to license a potential therapy to tamp down transplant rejection from the Hong Kong-based company Sino Biopharmaceutical.
The French pharma will get exclusive worldwide rights to develop, make and sell rovadicitinib, in a deal made via Sino’s subsidiary Chia Tai Tianqing Pharmaceutical. Sanofi is on the hook for up to $1.4 billion in milestone payments, plus possible double-digit tiered royalties, according to a Wednesday securities filing.
您已阅读19%（570字），剩余81%（2385字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。